← D.C. Law 26-115 · All reviewed explanations
D.C. Law 26-115 · DC District of Columbia · Section 2
HIV prevention: insurance discrimination, coverage and enforcement
When it was enacted
Enacted 2026-03-20 · Effective 2026-05-21 · Permanent law.
Official record datesBefore
The earlier insurance law already prohibited using personal characteristics to predict future AIDS or AIDS-related complex in coverage and pricing decisions. It also restricted condition-specific limitations on treatment of AIDS, HIV and related illnesses, and provided testing appeals, license sanctions and civil relief. This section expressly adds prescribed HIV prevention treatment to the discrimination and coverage protections, adds a specific fine for prohibited actions, and creates a separate prevention-coverage rule. The earlier code comparison does not establish that other federal or District laws previously allowed these practices.
Earlier official sourceAfter
An insurer may not consider an individual’s HIV prevention treatment taken under a valid prescriber’s order when deciding whether to issue, cancel or renew coverage, setting rates, premiums, benefits or reimbursable expenses, or in other insurance marketing or coverage. Health and disability policies may not single out HIV prevention treatment for exclusions, reductions, deductibles or coinsurance unless the provisions apply generally to all policy benefits; the separate new coverage rule is stricter for qualifying health benefit plans. For plans issued or renewed on or after January 1, 2027, insurers may not impose cost sharing, prior authorization, or medically unnecessary restrictions or delays on HIV prevention services, PEP or any formulation of PrEP. The exception applies to the extent that coverage without cost sharing would make a person in a high-deductible plan ineligible for a health savings account under federal tax law. Health benefit plans and insurers also may not use prescription information showing HIV prevention treatment to medically underwrite an individual enrollee’s premiums.
Enacted sourceIn plain English
PrEP is FDA-approved medication taken before possible HIV exposure; PEP is FDA-approved medication after possible recent exposure, for a person without HIV. Covered prevention services include CDC-recommended testing before prescribing, initial and follow-up services, medication for prevention-drug side effects, and medication self-management or adherence counseling. The law defines medically unnecessary restrictions as step therapy, waiting periods and preexisting-condition exclusions. Its insurer definition covers entities issuing, amending or renewing individual or group health, disability or life coverage in D.C. The separately incorporated health-benefit-plan definition excludes, among other categories, disability-only, long-term care, Medicare supplement, federal Medicare and federal employee contract coverage, dental-only, vision-only, specified-disease and other limited or supplemental policies; the health-plan coverage rule should not be read as applying to every insurance product. The section adds a $1,000–$10,000 fine per violation of the prohibited-actions provision, not an automatic payment of that amount to a patient. Existing license remedies and the Superior Court civil-relief provision remain. It updates testing responsibilities to the Health Department director and identifies the insurance commissioner as the appeal official; independent medical evidence may rebut a positive result and an insurer must disregard a result found not truly positive. It also permits mayoral rules for the new prevention-coverage section, without restarting the old 1986 rulemaking deadline.
Timing and applicability
The law took effect May 21, 2026. The January 1, 2027 issued-or-renewed threshold is expressly attached to the new no-cost-sharing/prior-authorization/restrictions rule; it is not a blanket delay for every amendment. This is an explanation of the enacted text. Actual policy applicability, federal-law interactions, enforcement, rules, appeals and later developments have not been fully reviewed; no particular claim outcome is promised.
Explanation reviewed 2026-10-23.
Read the official section text
2 The Prohibition of Discrimination in the Provision of Insurance Act of 1986, effective August 7, 1986 (D.C. Law 6-132; D.C. Official Code § 31-1601 et seq. ), is amended as follows: (a) Section 2 (D.C. Official Code § 31-1601) is amended as follows: (1) New paragraphs (2A) and (2B) are added to read as follows: (2A) "Baseline assessment" means any testing, as recommended by the U.S. Centers for Disease Control and Prevention, to be completed before prescribing HIV prevention medication, including screening tests for chlamydia, gonorrhea, syphilis, kidney function assessments, hepatitis B virus serology, and lipid profiles. (2B) "Commissioner" means the Commissioner of the Department of Insurance, Securities, and Banking. . (2) A new paragraph (3B) is added to read as follows: (3B) "Health benefit plan" shall have the same meaning as provided in section 101(20) of the Health Insurance Portability and Accountability Federal Law Conformity and No-Fault Motor Vehicle Insurance Act of 1998, effective April 13, 1999 (D.C. Law 12-209; D.C. Code § 31-3301.01(20)) . . (3) New paragraphs (5A) and (5B) are added to read as follows: (5A) "HIV prevention services" means medical services to prevent HIV and AIDS, including baseline assessments, initial and follow-up appointments and services, medication for the management of side effects associated with PrEP and PEP, and medication self-management or adherence counseling. (5B) "HIV prevention treatment" means medical treatment used to prevent HIV, including PrEP, PEP, and HIV prevention services. . (4) New paragraphs (7A) and (7B) are added to read as follows: (7A) "PrEP" means pre-exposure prophylaxis antiretroviral medication approved by the U.S. Food and Drug Administration ("FDA") used to prevent HIV in a person without HIV. (7B) "PEP" means post-exposure prophylaxis antiretroviral medication approved by the FDA used to prevent HIV in a person without HIV who may have been recently exposed to HIV. . (b) Section 4 (D.C. Official Code § 31-1603) is amended as follows: (1) Subsection (b) is amended to read as follows: (b) (1) In determining whether to issue, cancel, or renew insurance coverage, an insurer may not: (A) Use age, marital status, geographic area of residence, occupation, sex, sexual orientation, gender identity or expression, or any similar factor or combination of factors for the purpose of seeking to predict whether any individual may in the future develop AIDS or ARC; or (B) Take into consideration an individual's use of HIV prevention treatment when taken pursuant to a valid prescriber's order. (2) In determining rates, premiums, dues, assessments, benefits covered, or expenses reimbursable, or in any other aspect of insurance marketing or coverage, an insurer may not: (A) Use age, marital status, geographic area of residence, occupation, sex, sexual orientation, gender identity or expression, or any similar factor or combination of factors for the purpose of seeking to predict whether any individual may in the future develop AIDS or ARC; or (B) Take into consideration an individual's use of HIV prevention treatment when taken pursuant to a valid prescriber's order. . (2) Subsection (c) is amended to read as follows: (c) No health or disability insurance policy or contract shall contain any exclusion, reduction, other limitation of coverage, deductibles, or coinsurance provisions related to HIV prevention treatment or the care and treatment of AIDS, ARC, HIV infection, or any illness or disease arising from these medical conditions, unless the provisions apply generally to all benefits under the policy or contract. . (c) Section 5 (D.C. Official Code § 31-1604) is amended as follows: (1) Subsection (a) is amended as follows: (A) Paragraph (1) is amended by striking the phrase "District of Columbia Commissioner of Public Health ("Commissioner")" and inserting the phrase "Director of the Department of Health ("Director")" in its place. (B) Paragraph (2) is amended by striking the word "Commissioner" and inserting the word "Director" in its place. (2) Subsection (b) is amended as follows: (A) Paragraph (1) is amended to read as follows: (b) (1) A named insured who tests positive under the testing protocol certified by the Director may appeal to the Commissioner to review the testing procedures and results, and may present additional medical evidence, including the results of similar tests for exposure to the probable causative agent of AIDS that the named insured independently obtains, to rebut the positive test results. If the Commissioner determines that the result of the test of the proposed insured is not a true positive, the Commissioner shall order the insurer from which the applicant sought coverage to disregard the positive test result. The Commissioner shall, when necessary, request the advice of the Director in making this determination. . (B) Paragraph (3) is amended by striking the word "Commissioner" and inserting the word "Director" in its place. (d) Section 9 (D.C. Official Code § 31-1608) is amended by adding a new subsection (b-1) to read as follows: (b-1) Any person who violates section 4 shall be fined not less than $1,000, and not more than $10,000 for each violation. . (e) Section 10 (D.C. Official Code § 31-1609) is amended as follows: (1) The existing text is designated as subsection (a). (2) A new subsection (b) is added to read as follows: (b) The Mayor, pursuant to Title I of the District of Columbia Administrative Procedure Act, approved October 21, 1968 (82 Stat. 1204; D.C. Official Code § 2-501 et seq. ) , may issue rules to implement the provisions of section 12 . . (f) A new section 12 is added to read as follows: 12 Coverage for HIV prevention treatment. (a) (1) Except as otherwise provided in subsection (b) of this section, for health benefit plans issued or renewed on or after January 1, 2027, an insurer may not impose cost sharing, require prior authorization, or impose any medically unnecessary restrictions or delays for the coverage of HIV prevention services, PEP, or any formulation of PrEP. (b) Subsection (a) of this section shall not apply to the extent that coverage without cost-sharing would disqualify an individual receiving coverage under a high deductible health plan from eligibility for a health savings account pursuant to 26 U.S.C. § 223. (c) No health benefit plan or insurer may use prescription information indicating the use of HIV prevention treatment to medically underwrite premiums for specific enrollees. (d) For the purposes of this section, the term "medically unnecessary restrictions" means step therapy, waiting periods, or preexisting condition exclusions. Aug. 7, 1986, D.C. Law 6-132, § 12 .Pinned official bulk source
Interpretations & later changes
Later-law and court review may be incomplete. Absence of an entry does not establish that the original provision remains in force.
No separately reviewed later development is published here yet.